Repligen Corporation with ticker code (RGEN) have now 11 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $225.00 and $160.00 calculating the average target price we see $193.16. Now with the previous closing price of $152.95 this would imply there is now a potential upside of 26.3%. There is a 50 day moving average of $138.59 and the 200 moving average now moves to $165.67. The market capitalization for the company is 8.36B. The price for the stock stands currently at: $149.20 USD
The potential market cap would be $10,552,623,383 based on the market consensus.
The company has a dividend yield of 5.38%. Other points of data to note are a P/E ratio of -, revenue per share of $10.79 and a 0.19% return on assets.
Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company’s bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.
